U. Parikh

Michele D. Sobolewski, Janet S. Lee, J. Mellors, 2021, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Randomized, placebo controlled phase I trial of the safety, pharmacokinetics, pharmacodynamics and acceptability of a 90 day tenofovir plus levonorgestrel vaginal ring used continuously or cyclically in women: The CONRAD 138 study

G. Doncel, D. Erikson, R. Fichorova, 2022, PloS one.

Postexposure Protection of Macaques from Vaginal SHIV Infection by Topical Integrase Inhibitors

W. Heneine, D. Hazuda, U. Parikh, 2014, Science Translational Medicine.

Integrase Inhibitors Postexposure Protection of Macaques from Vaginal SHIV Infection by

W. Heneine, D. Hazuda, U. Parikh, 2014 .

The 3′-Azido Group Is Not the Primary Determinant of 3′-Azido-3′-deoxythymidine (AZT) Responsible for the Excision Phenotype of AZT-resistant HIV-1*

J. Mellors, R. Schinazi, N. Sluis-Cremer, 2005, Journal of Biological Chemistry.

An assessment of Nano-RECall: Interpretation of Oxford Nanopore sequence data for HIV-1 drug resistance testing

P. Harrigan, U. Parikh, C. Woods, 2022, bioRxiv.

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel

Ross D. Cranston, T. Holtz, A. Carballo-Diéguez, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

HIV-1 drug resistance resulting from antiretroviral therapy far exceeds that from pre-exposure prophylaxis.

J. Mellors, U. Parikh, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial

A. Perelson, S. Pedersen, R. Ribeiro, 2022, Nature Microbiology.

Deciphering the Effects of Injectable Pre-exposure Prophylaxis for Combination Human Immunodeficiency Virus Prevention

R. Glaubius, U. Abbas, J. Mellors, 2016, Open forum infectious diseases.

Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.

Ashley J. Mayo, J. Baeten, A. van der Straten, 2021, The lancet. HIV.

Long-term follow-up of HIV seroconverters in microbicide trials – rationale, study design, and challenges in MTN-015

F. Martinson, S. Riddler, E. Livant, 2016, HIV clinical trials.

Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19

E. Daar, C. Moser, J. Currier, 2022, Open forum infectious diseases.

In Vitro Selection and Analysis of Human Immunodeficiency Virus Type 1 Resistant to Derivatives of β-2′,3′-Didehydro-2′,3′-Dideoxy-5-Fluorocytidine

J. Mellors, R. Schinazi, C. K. Chu, 2005, Antimicrobial Agents and Chemotherapy.

Prospective Evaluation of Coronavirus Disease 2019 (COVID-19) Vaccine Responses Across a Broad Spectrum of Immunocompromising Conditions: the COVID-19 Vaccination in the Immunocompromised Study (COVICS)

D. Angus, J. Luketich, M. Schwartz, 2022, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2–specific memory T cell responses

A. Sette, E. Daar, S. Crotty, 2022, JCI insight.

Antagonism between the HIV-1 reverse-transcriptase mutation K65R and thymidine-analogue mutations at the genomic level.

J. Mellors, U. Parikh, Douglas C Barnas, 2006, The Journal of infectious diseases.

Molecular mechanisms of bidirectional antagonism between K65R and thymidine analog mutations in HIV-1 reverse transcriptase

J. Mellors, N. Sluis-Cremer, U. Parikh, 2007, AIDS.

Molecular Mechanism by Which the K70E Mutation in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Nucleoside Reverse Transcriptase Inhibitors

J. Mellors, N. Sluis-Cremer, U. Parikh, 2006, Antimicrobial Agents and Chemotherapy.

Trends in Pretreatment HIV-1 Drug Resistance in Antiretroviral Therapy-naive Adults in South Africa, 2000–2016: A Pooled Sequence Analysis

D. Katzenstein, R. Shafer, D. Pillay, 2019, EClinicalMedicine.

ANTAGONISTIC EVOLUTIONARY PATHWAYS OF HIV-1 RESISTANCE TO NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS: A VIROLOGICAL, BIOCHEMICAL AND CLINICAL INVESTIGATION

U. Parikh, 2005 .

How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?

J. Mellors, U. Parikh, 2022, Current opinion in HIV and AIDS.

Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.

Ashley J. Mayo, J. Baeten, A. van der Straten, 2016, The New England journal of medicine.

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?

J. Mellors, U. Parikh, Catherine A Koss, 2022, Current HIV/AIDS Reports.

Frequent cross-resistance to rilpivirine among subtype C HIV-1 from first-line antiretroviral therapy failures in South Africa

J. Mellors, C. Brumme, C. Wallis, 2018, Antiviral chemistry & chemotherapy.

Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.

R. Glaubius, U. Abbas, J. Mellors, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).

J. Mellors, M. Boffito, D. Back, 2016, The Journal of infectious diseases.

Performance of Swabs, Lavage, and Diluents to Quantify Biomarkers of Female Genital Tract Soluble Mucosal Mediators

J. Mellors, J. Marrazzo, C. Hendrix, 2011, PloS one.

Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the MTN-020/ASPIRE Phase III Trial of the Dapivirine Vaginal Ring.

Ashley J. Mayo, J. Baeten, J. Mellors, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Casting a Wide Net: HIV Drug Resistance Monitoring in Pre-Exposure Prophylaxis Seroconverters in the Global Evaluation of Microbicide Sensitivity Project

J. Mellors, B. Chohan, Everline C Bosek, 2022, Global Health: Science and Practice.

HIV Drug Resistance Patterns at the Epicentre of the HIV-1 Epidemic in Kwazulu-Natal, South Africa 2003-2013

P. Kiepiela, G. Ramjee, M. Gordon, 2014 .

Janet S. Lee, J. Mellors, P. Bjorkman, 2021, Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America.

Complete Protection from Repeated Vaginal Simian-Human Immunodeficiency Virus Exposures in Macaques by a Topical Gel Containing Tenofovir Alone or with Emtricitabine

W. Heneine, P. Guenthner, U. Parikh, 2009, Journal of Virology.

PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project

Gabrielle E. O'Malley, J. Baeten, S. Delany-Moretlwe, 2022, Journal of the International AIDS Society.

Brief Report: Quantifiable Plasma Tenofovir Among South African Women Using Daily Oral Pre-exposure Prophylaxis During the ECHO Trial

J. Baeten, R. Heffron, H. Rees, 2022, Journal of acquired immune deficiency syndromes.

Characteristics Associated with HIV Drug Resistance Among Women Screening for an HIV Prevention Trial in KwaZulu-Natal, South Africa

P. Kiepiela, C. Kelly, G. Ramjee, 2015, AIDS and Behavior.

Objective Measurement of Inaccurate Condom Use Reporting Among Women Using Depot Medroxyprogesterone Acetate for Contraception

J. Baeten, R. Heffron, J. Mellors, 2017, AIDS and Behavior.

Prevalence of HIV-1 Drug Resistance among Women Screening for HIV Prevention Trials in KwaZulu-Natal, South Africa (MTN-009)

J. Mellors, P. Kiepiela, C. Kelly, 2013, PloS one.

Y Chromosome and HIV DNA Detection in Vaginal Swabs as Biomarkers of Semen and HIV Exposure in Women

J. Mellors, B. Richardson, S. A. Abdool Karim, 2014, Sexually transmitted diseases.

In Vitro Activity of Structurally Diverse Nucleoside Analogs against Human Immunodeficiency Virus Type 1 with the K65R Mutation in Reverse Transcriptase

J. Mellors, R. Schinazi, C. K. Chu, 2005, Antimicrobial Agents and Chemotherapy.

Risk of HIV-1 acquisition among women who use diff erent types of injectable progestin contraception in South Africa: a prospective cohort study.

J. Baeten, A. van der Straten, B. Richardson, 2015, The lancet. HIV.

Prospective evaluation of COVID-19 vaccine responses across a broad spectrum of immunocompromising conditions: the COVICS study.

D. Angus, J. Luketich, M. Schwartz, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

PSA DENSITY IS BETTER INDICATOR FOR PREDICTING PROSTATE CARCINOMA THAN TOTAL PSA VALUE IN GRAY ZONE PSA LEVELS

U. Parikh, D. Vaishali, Pipaliya, 2020 .

Cost-effectiveness of easy-access, risk-informed oral pre-exposure prophylaxis in HIV epidemics in sub-Saharan Africa: a modelling study

T. Hallett, D. Havlir, J. Mellors, 2022, The lancet. HIV.

The fourth generation AlereTM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples.

J. Marrazzo, Z. Chirenje, C. Kelly, 2017, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy

R. Ribeiro, E. Daar, D. Smith, 2021, medRxiv.

HIV‐1 drug resistance among individuals who seroconverted in the ASPIRE dapivirine ring trial

J. Baeten, D. Szydlo, J. Mellors, 2021, Journal of the International AIDS Society.

Nano‐RECall provides an integrated pipeline for HIV‐1 drug resistance testing from Oxford Nanopore sequence data

P. Harrigan, U. Parikh, C. Woods, 2023, Tropical medicine & international health : TM & IH.

High Levels of Pretreatment HIV-1 Drug Resistance Mutations Among South African Women Who Acquired HIV During a Prospective Study

J. Baeten, R. Heffron, H. Rees, 2022, Journal of acquired immune deficiency syndromes.

Antiretroviral-based HIV prevention strategies for women

J. Marrazzo, Z. Chirenje, U. Parikh, 2010, Expert review of anti-infective therapy.

Discordance between Etravirine Phenotype and Genotype-Based Predicted Phenotype for Subtype C HIV-1 from First-Line Antiretroviral Therapy Failures in South Africa

P. Harrigan, J. Mellors, K. McCormick, 2020, Antimicrobial Agents and Chemotherapy.

Tenofovir-based preexposure prophylaxis for HIV infection among African women.

A. van der Straten, N. Mgodi, J. Piper, 2015, The New England journal of medicine.

Early antiviral CD4 and CD8 T cell responses are associated with upper respiratory tract clearance of SARS-CoV-2

S. Crotty, C. Moser, D. Weiskopf, 2023, bioRxiv.

Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa.

R. Glaubius, U. Abbas, J. Mellors, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immune Status and SARS-CoV-2 Viral Dynamics.

E. Daar, C. Moser, J. Currier, 2023, The Journal of infectious diseases.

Frequent Cross-Resistance to Dapivirine in HIV-1 Subtype C-Infected Individuals after First-Line Antiretroviral Therapy Failure in South Africa

J. Mellors, P. Harrigan, C. Brumme, 2016, Antimicrobial Agents and Chemotherapy.

A Multiple Dose Phase 1 Assessment of Rilpivirine Long-Acting in a Model of Pre-Exposure Prophylaxis against HIV.

Ross D. Cranston, Kaleab Z. Abebe, S. Khoo, 2019, AIDS research and human retroviruses.